Patients with refractory or relapsed multiple myeloma usually develop resistance to the two approved BCMA-targeting chimeric antigen receptor (CAR) T cells. A preliminary study of a new CAR T-cell therapy that zeroes in on the GPRC5D protein on multiple myeloma cells suggests that this approach is safe and effective. All 10 patients treated with the GPRC5D-targeting cells showed responses.

中文翻译：

---

GPRC5D 定向 CAR 产生 100% 响应率

难治性或复发性多发性骨髓瘤患者通常会对两种已批准的 BCMA 靶向嵌合抗原受体 (CAR) T 细胞产生耐药性。针对多发性骨髓瘤细胞上的 GPRC5D 蛋白的新型 CAR T 细胞疗法的初步研究表明，这种方法是安全有效的。所有 10 名接受 GPRC5D 靶向细胞治疗的患者均显示出反应。